A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
|Articles|March 31, 2023
Johnson & Johnson Halts Phase 3 RSV Vaccine Trial
Author(s)John Parkinson
After assessing the landscape, the company is leaving the adult RSV vaccine market.
Advertisement
This week, the Janssen Pharmaceutical Companies of Johnson & Johnson announced it had stopped its EVERGREEN phase 3 trial for its RSV investigational vaccine that was developed for adults 60 years and older.
The company said it decided to do so after reviewing the current adult RSV market.
“By periodically refocusing our portfolio, Janssen ensures that we are deeply invested in products that have the power to transform patients’ lives,” Bill Hait, MD, PhD, executive vice president, chief external innovation and Medical officer and interim head, Janssen R&D, said in a statement. “We remain focused on advancing our differentiated pipeline, improving the lives of millions of patients and developing new modalities in areas with the greatest unmet medical need.”
The decision to discontinue the RSV adult vaccine program is part of a broader effort to make strategic choices for its pipeline and research and development investments to focus on medicines with the greatest potential benefit to patients, according to the company’s announcement.
In the last few weeks, there has been a lot of movement in this market, especially from GSK and Pfizer. They each had a meeting with the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review their data. After doing so, the committee voted to recommend each of the RSV vaccine candidates, which were developed for the senior population.
Decisions on potential FDA approvals for both vaccines could happen this spring.
Advertisement
Related to this article
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
Advertisement
Advertisement
Trending on Contagion Live
1
Washington State Reports First US Avian Influenza Death of 2026
2
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
3
Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37
4
FDA Approves Voceryq, First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
5